Skip to main content
. Author manuscript; available in PMC: 2015 Nov 12.
Published in final edited form as: Clin Immunol. 2010 Dec 3;138(2):201–211. doi: 10.1016/j.clim.2010.11.002

Figure 4.

Figure 4

Enhancement of activation-induced T cell proliferation by lenalidomide: dependence on IL-2 signaling. Each point and bar in the left-hand frame and each column and bar in the right-hand frame depict the mean±S.D. of the results of proliferation assays of activated T cells from the same five old subjects as in Figure 5. Incubation with anti-CD3 + anti-CD28 antibodies was for two days without (control = 100%) or with lenalidomide prior to addition of BrdU. The mean±S.D. of control values was 0.468±0.166 AU (450 nm–690 nm). Statistical significance was calculated and depicted as in Figure 1, with comparisons between values with lenalidomide and the 100% control for points in the left-hand frame and between values without and with a-IL-2 R monoclonal antibody for each set of two columns in the right-hand frame.